These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 31923859)

  • 21. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
    Chen Y; Ernst P
    Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction.
    Karatas H; Townsend EC; Bernard D; Dou Y; Wang S
    J Med Chem; 2010 Jul; 53(14):5179-85. PubMed ID: 20575550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5.
    Senisterra G; Wu H; Allali-Hassani A; Wasney GA; Barsyte-Lovejoy D; Dombrovski L; Dong A; Nguyen KT; Smil D; Bolshan Y; Hajian T; He H; Seitova A; Chau I; Li F; Poda G; Couture JF; Brown PJ; Al-Awar R; Schapira M; Arrowsmith CH; Vedadi M
    Biochem J; 2013 Jan; 449(1):151-9. PubMed ID: 22989411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
    Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
    Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
    Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
    J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex.
    Patel A; Dharmarajan V; Vought VE; Cosgrove MS
    J Biol Chem; 2009 Sep; 284(36):24242-56. PubMed ID: 19556245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
    Chen CW; Armstrong SA
    Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.
    Li BE; Ernst P
    Exp Hematol; 2014 Dec; 42(12):995-1012. PubMed ID: 25264566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
    Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting human SET1/MLL family of proteins.
    Vedadi M; Blazer L; Eram MS; Barsyte-Lovejoy D; Arrowsmith CH; Hajian T
    Protein Sci; 2017 Apr; 26(4):662-676. PubMed ID: 28160335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance.
    Huo H; Magro PG; Pietsch EC; Patel BB; Scotto KW
    Cancer Res; 2010 Nov; 70(21):8726-35. PubMed ID: 20861184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
    Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
    Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MLL1/WDR5 complex in leukemogenesis and epigenetic regulation.
    Wu M; Shu HB
    Chin J Cancer; 2011 Apr; 30(4):240-6. PubMed ID: 21439245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
    Heikamp EB; Henrich JA; Perner F; Wong EM; Hatton C; Wen Y; Barwe SP; Gopalakrishnapillai A; Xu H; Uckelmann HJ; Takao S; Kazansky Y; Pikman Y; McGeehan GM; Kolb EA; Kentsis A; Armstrong SA
    Blood; 2022 Feb; 139(6):894-906. PubMed ID: 34582559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
    Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
    Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.
    Klossowski S; Miao H; Kempinska K; Wu T; Purohit T; Kim E; Linhares BM; Chen D; Jih G; Perkey E; Huang H; He M; Wen B; Wang Y; Yu K; Lee SC; Danet-Desnoyers G; Trotman W; Kandarpa M; Cotton A; Abdel-Wahab O; Lei H; Dou Y; Guzman M; Peterson L; Gruber T; Choi S; Sun D; Ren P; Li LS; Liu Y; Burrows F; Maillard I; Cierpicki T; Grembecka J
    J Clin Invest; 2020 Feb; 130(2):981-997. PubMed ID: 31855575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WDR5 interacts with mixed lineage leukemia (MLL) protein via the histone H3-binding pocket.
    Song JJ; Kingston RE
    J Biol Chem; 2008 Dec; 283(50):35258-64. PubMed ID: 18840606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia.
    Chen Y; Anastassiadis K; Kranz A; Stewart AF; Arndt K; Waskow C; Yokoyama A; Jones K; Neff T; Lee Y; Ernst P
    Cancer Cell; 2017 Jun; 31(6):755-770.e6. PubMed ID: 28609655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.
    Howard GC; Wang J; Rose KL; Jones C; Patel P; Tsui T; Florian AC; Vlach L; Lorey SL; Grieb BC; Smith BN; Slota MJ; Reynolds EM; Goswami S; Savona MR; Mason FM; Lee T; Fesik S; Liu Q; Tansey WP
    Elife; 2024 Apr; 12():. PubMed ID: 38682900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.